Skip to content
cccskills
FreePublished on GitHub

es-check-hormone-levels-target-range

Determines if current hormone levels are within target range for affirmed gender (e.g., testosterone 400-700 ng/dL for transgender males, estradiol 100-200 pg/mL for transgender females). Triggers include patient on hormone therapy and time for level check.

The English summary is being prepared. Showing the original description.

See how to install

Files included (1)

  • SKILL.md2.3 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Check if hormone levels are in target range for affirmed gender

STEP 1 — Gather Information

Collect patient's affirmed gender, current hormone therapy regimen (type, dose, frequency), timing of last dose, and most recent serum testosterone (for transgender males) or estradiol (for transgender females) level.

STEP 2 — Rule In / Rule Out

Is the patient currently receiving gender-affirming hormone therapy? If yes, proceed to step 3; if no, hormone level check is not indicated for this purpose.

STEP 3 — Classify or Stratify

Compare measured hormone level to target range: for transgender males, target testosterone 400–700 ng/dL; for transgender females, target estradiol 100–200 pg/mL. Also verify suppression of endogenous sex steroids (testosterone <50 ng/dL in transgender females; estradiol <50 pg/mL in transgender males) if clinically relevant.

STEP 4 — Decide

If hormone level is within target range, continue current regimen. If below target, consider dose increase after assessing adherence and timing. If above target, evaluate for adverse effects and consider dose reduction or dosing interval adjustment.

Clinical Guardrails / Mimics / Pitfalls

Do not adjust dose based on a single out-of-range level without confirming timing relative to dose and assay reliability. Avoid supraphysiologic dosing to reduce thrombotic or erythrocytosis risk. Ensure assays are ultrasensitive and performed at appropriate trough/peak times as per formulation.

Concrete Clinical Example

A transgender male receives testosterone enanthate 100 mg IM weekly. Laboratory shows testosterone 350 ng/dL (below target 400–700 ng/dL). After confirming adherence and proper trough sampling, dose is increased to 125 mg weekly.

Source: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, DOI:10.1210/jc.2017-01658

TODO: consider adding scripts/calc.py for the es-check-hormone-levels-target-range calculator

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill